Eluxadoline for Irritable Bowel Syndrome with Diarrhoea -

Eluxadoline for Irritable Bowel Syndrome with Diarrhoea
Information type: Randomised controlled trials
Source: New England Journal of Medicine
Specialities: Gastrointestinal disorders
Summary
In 2 RCTs (n=2427) of 26 and 52 weeks duration, eluxadoline, a new oral agent with mixed opioid effects, reduced symptoms of IBS with diarrhoea in men and women vs. placebo, with sustained efficacy over 6 months in patients who received the 100-mg dose twice daily.
UKMi comment
Eluxadoline, a μ- and κ-opioid receptor agonist and a δ-opioid receptor antagonist, was filed for approval in EU in June 2015.
Related links: